Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 9, 2015, Pages 1613-1631

  Golubovskaya, Vita ^a   O’Brien, Shalana ^a   Ho, Baotran ^a   Heffler, Melissa ^a   Conroy, Jeffrey ^a   Hu, Quang ^a   Wang, Dan ^a   Liu, Song ^a   Cance, William G ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Autophosphorylation; Cancer; Focal adhesion kinase; Inhibitor; Resistance

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; ALDEHYDE DEHYDROGENASE ISOENZYME 1A3; ANTINEOPLASTIC AGENT; FOCAL ADHESION KINASE INHIBITOR; HERMES ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; Y 15; 1,2,4,5-BENZENETETRAAMINE; ABCB1 PROTEIN, HUMAN; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE (NAD(P)+); ANILINE DERIVATIVE; CD44 PROTEIN, HUMAN; FOCAL ADHESION KINASE 1; MULTIDRUG RESISTANCE PROTEIN; PROTEIN KINASE INHIBITOR; PTK2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; BIOINFORMATICS; CANCER CELL; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENIC ACTIVITY; CELL VIABILITY; CLONOGENESIS; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIZATION; SIGNAL TRANSDUCTION; THYROID CANCER; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; COLONIC NEOPLASMS; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; NUDE MOUSE; PHOSPHORYLATION; THYROID NEOPLASMS; TUMOR CELL LINE;

ALDEHYDE OXIDOREDUCTASES; ANILINE COMPOUNDS; ANIMALS; ANTIGENS, CD44; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FOCAL ADHESION KINASE 1; HUMANS; MICE; MICE, NUDE; P-GLYCOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; THYROID NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939272671     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-1924-3     Document Type: Article

References (27)

1. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168
2. Beierle EA, Ma X, Stewart J, Nyberg C, Trujillo A et al (2010) Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle 9:1005–1015
3. Bourguignon LY, Peyrollier K, Xia W, Gilad E (2008) Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283:17635–17651
4. Cance WG, Kurenova E, Marlowe T, Golubovskaya V (2013) Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics. Sci Signal 6:pe10
5. Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q et al (2010) Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 5:e10277
6. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J et al (2008) Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 3:e2428
7. Fonar Y, Gutkovich YE, Root H, Malyarova A, Aamar E et al (2011) Focal adhesion kinase protein regulates Wnt3a gene expression to control cell fate specification in the developing neural plate. Mol Biol Cell 22:2409–2421
8. Gabarra-Niecko V, Schaller MD, Dunty JM (2003) FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 22:359–374
9. Golubovskaya VM, Cance WG (2007) Focal adhesion kinase and p53 signaling in cancer cells. Int Rev Cytol 263:103–153
10. Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A et al (2008) A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the Y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 51:7405–7416
11. Golubovskaya VM, Conway-Dorsey K, Edmiston SN, Tse CK, Lark AA et al (2009) FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer 125:1735–1738
12. Golubovskaya VM, Huang G, Ho B, Yemma M, Morrison CD et al (2013) Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide. Mol Cancer Ther 12:162–172
13. Heffler M, Golubovskaya VM, Dunn KM, Cance W (2013a) Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy. Cancer Biol Ther 14:761–772
14. Heffler M, Golubovskaya V, Conroy J, Liu S, Wang D et al (2013b) Fak and has inhibition synergistically decrease colon cancer cell viability and affect expression of critical genes. Anticancer Agents Med Chem 13:584–594
15. Ho B, Olson G, Figel S, Gelman I, Cance WG et al (2012) Nanog increases focal adhesion kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated. J Biol Chem 287:18656–18673
16. Hochwald SN, Nyberg C, Zheng M, Wood C, Massoll NA et al (2009) A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle 8:2435–2443
17. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G et al (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69:3382–3389
18. Illc D, Furuta Y, Kanazawa S, Takeda N, Sobue K et al (1995) Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377:539–544
19. Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T et al (2013) Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst 105:1485–1495
20. Krech T, Scheuerer E, Geffers R, Kreipe H, Lehmann U (2012) ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells. Cancer Lett 315:153–160
21. Lark AL, Livasy CA, Dressler L, Moore DT, Millikan RC et al (2005) High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod Pathol 18:1289–1294
22. Luo M, Fan H, Nagy T, Wei H, Wang C et al (2009) Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res 69:466–474
23. Luo M, Zhao X, Chen S, Liu S (2013) Wicha MS, (2013) Distinct FAK activities determine progenitor and mammary stem cell characteristics. Cancer Res 69:466–474
24. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M et al (2011) Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 29:32–45
25. Owens LV, Xu L, Craven RJ, Dent GA, Weiner TM, Kornberg L et al (1995) Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res 55:2752–2755
26. Scheel C, Weinberg RA (2012) Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 22:396–403
27. Xu L-H, Yang X-H, Bradham CA, Brenner DA, Baldwin AS et al (2000) The focal adhesion kinase suppresses transformation-associated, anchorage-Independent apoptosis in human breast cancer cells. J Biol Chem 275:30597–30604